Kolexia
Aldabbagh Kais Oncologie médicale
Aldabbagh Kais
Oncologie médicale
Cabinet libéral
Compiègne, France
125 Activités
2.3 K Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs de la prostate Tumeurs prostatiques résistantes à la castration Leucopénie Neutropénie Ostéosarcome Alopécie COVID-19 Sarcomes Tumeurs du sein

Collaborateurs

Voir plus
Geraud Marc
Geraud Marc
Cabinet libéral, Compiègne, France
Charleux Fabrice
Charleux Fabrice
Hôpital Cochin, Paris, France
Durigova Anna
Durigova Anna
Centre Hospitalier de Compiègne, Compiègne, France
Dupic Guillaume
Dupic Guillaume
Cabinet libéral, Compiègne, France

Industries

Voir plus
B3TSI
123 collaboration(s)
Dernière en 2023
A+A
52 collaboration(s)
Dernière en 2023
Novartis
9 collaboration(s)
Dernière en 2023
AstraZeneca
8 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical Trial.
JAMA oncology   26 octobre 2023
1808P Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel every 2 weeks (16 mg/m2) versus every 3 weeks (25 mg/m2) in the CABASTY phase III trial
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
LBA77 5-fluorouracil and oxaliplatin with or without docetaxel in the first-line treatment of HER2 negative locally advanced (LA) unresectable or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma (GASTFOX-PRODIGE 51): A randomized phase III trial sponsored by the FFCD
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
POCHI: Pembrolizumab in Combination With Xelox Bevacizumab in Patients With Microsatellite Stable Mestatic Colorectal Cancer and a High Immune Infiltrate : a Proof of Concept Study
Essai Clinique (Fédération Francophone de Cancérologie Digestive)   16 août 2023
1363MO Cabazitaxel every 2 weeks versus every 3 weeks in older patients with metastatic castration-resistant prostate cancer (mCRPC): The CABASTY randomized phase III trial
Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022   01 septembre 2022
CABASTY: Randomized Multicenter, Phase III Trial Evaluating the Safety of 2 Schedules of Cabazitaxel (Bi-weekly Versus Tri-weekly) Plus Prednisone in Elderly Men (≥ 65years) With mCRPC Previously Treated With a Docetaxel-containing Regimen
Essai Clinique (Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie)   09 mai 2022
Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19).
European journal of cancer (Oxford, England : 1990)   08 octobre 2020
Compiègne : un cocon pour choyer les rescapés du cancer
Le Parisien   16 janvier 2020
Osteosarcomas of the mandible: multidisciplinary management of a rare tumor of the young adult a cooperative study of the GSF-GETO, Rare Cancer Network, GETTEC/REFCOR and SFCE.
Annals of oncology : official journal of the European Society for Medical Oncology   06 novembre 2012
Sarcoligo, impact du traitement local ablatif (chirurgie, radiothérapie, radiofréquence, etc.) des oligométastases sur la survie globale des patients atteints de sarcomes
23e Congrès national de la Société française de radiothérapie oncologique (SFRO)   01 septembre 2012